Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

NCT04514510 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

NIH

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Isoquercetin
DRUG: Placebo

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborators

[object Object]